Ionis is a company focused on the discovery, development, and delivery of genetic medicines.

Ionis

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

Ionis Pharmaceuticals, Inc.

The U.S. Food and Drug Administration accepted our New Drug Application for the treatment of familial chylomicronemia syndrome (#FCS) and granted Priority Review. In addition, enrollment completed in the Phase 3 severe hypertriglyceridemia (#sHTG) clinical program. 
 
Read more: https://lnkd.in/epHKFCF3

Today, we announced an expanded license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE).
 
Read more about this announcement and what it means for people living with this serious #RareDisease: https://lnkd.in/en24U9EJ

Asian Pacific Islander Desi American (APIDA) Heritage Month is a time to honor the APIDA communities’ experiences, histories and cultures. We kicked off celebrations with our second annual employee-contributed art exhibit hosted by our DEI Advocates ERG. All Ions connected to the APIDA community were invited to share their art and culture at the event. Scroll through to see and hear more from our Ions.

At Ionis, we stand firm in our commitment to steward an inclusive and supportive environment where everyone can thrive. We embrace the authenticity, diversity and unique perspectives of our LGBTQ+ colleagues - during Pride month and throughout the year. By championing these values, we strengthen our teams, drive innovation and build a stronger, more compassionate organization for all. #HappyPride 

(Video taken June 4th at our flag raising on our Carlsbad campus and followed by a Pride celebration lunch with activities organized by our LGBTQIA+ ERG.)

Last week, we had the incredible opportunity to co-sponsor the second annual ‘LGBTQ+ Scholars in STEM’, a San Diego-based event aimed at empowering the next generation of biotech leaders! It was an evening filled with insightful discussions and meaningful connections.
 
Our very own JP Mac Donald and Archit Rastogi spoke on panels alongside biotech leaders from our hosts Illumina as well as Bristol Myers Squibb, Crinetics Pharmaceuticals, Takeda, Travere Therapeutics, and OUTbio San Diego. Panelists delved into the intricacies of making the leap from academia to industry, while also shedding light on LGBTQ+ inclusivity in the workplace.
 
Events like these are crucial for fostering diversity and inclusion in our industry and provide a platform for LGBTQIA+ individuals to share their unique career experiences and insights. It's truly inspiring to witness the passion and drive that these individuals bring to their work, reminding us of the importance of creating inclusive environments where everyone can thrive.
 
A big thank you to everyone who joined us for this event and continues to champion diversity and inclusion in STEM.

#GlobalFattyLiverDay, led by Global Liver Institute, is an annual moment in time to educate about fatty liver disease, which impacts over 115 million people globally. 

#FattyLiverDisease may lead to serious complications like cirrhosis, liver cancer or the need for a liver transplant. Due to the lack of obvious symptoms, people impacted by this condition may struggle to receive a diagnosis.

Join us in raising awareness of this progressive condition.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Nov 30, 2024 12:52 AM	0d92d317
public peers	general	Jul 25, 2024 10:53 AM	baeb7e40
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Nov 29, 2024 2:39 AM	74902c0b
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b07860d2
crunchbase profile	general
li profile	general	Jul 25, 2024 10:53 AM	33bcc331
translate crunchbase fundingrounds	general
peers	general	Jul 25, 2024 10:53 AM	d3d21776
news basic	general	Nov 28, 2024 2:45 PM	59e38775
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IONIS

Ionis